Genentech’s Vabysmo (faricimab-svoa) Receives the US FDA’s Approval for the Treatment of Retinal Vein Occlusion
Shots:
- The approval was based on the P-III (BALATON) in 553 patients with branch retinal vein occlusion and (COMINO) studies in 729 patients with central retinal or hemiretinal vein occlusion evaluating Vabysmo vs aflibercept
- The results showed that patients treated with the monthly treatment with Vabysmo achieved early and sustained improvement in vision in patients with branch and central RVO & met the 1EPs of non-inferior visual acuity gains at 24wks. & also showed that patients achieved rapid and robust drying of retinal fluid
- The therapy was well tolerated in both studies & the safety profile was consistent with prior results. The therapy was approved in 80+ countries globally for wet AMD and DME
Ref: Businesswire | Image: Genentech
Related News:- Roche Reports P-III Studies (BALATON) & (COMINO) Results of Vabysmo (faricimab) for the Treatment of Retinal Vein Occlusion
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
